

## GLOBAL MEDI-CAL DRUG USE REVIEW (DUR) BOARD MEETING AGENDA

## State of California DEPARTMENT OF HEALTH CARE SERVICES

Notice is hereby given that the **Global Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, May 21, 2019,** at the following location:

Department of Health Care Services 1700 K Street 1<sup>st</sup> Floor Conference Room Sacramento, CA 95814 9:30 AM-3:00 PM

All times shown are approximate and are subject to change Registration link to attend meeting via webinar

Report Type*	Agenda Item	Presenter	Time
С	Welcome/Introductions/Roll Call	Pauline Chan, RPh, MBA	930- 940
I/D	2. Call to Order/Guidelines	Randall Stafford, MD, PhD	940- 945
R/A/D	3. Review and Approval of Previous Minutes from February 26, 2019	Randall Stafford, MD, PhD	945- 950
	4. Old Business		
I/D	<ul> <li>a. Review of Board Action Items from February 26, 2019</li> <li>b. Recommended Action Items for MCPs from February 26, 2019</li> </ul>	Pauline Chan, RPh, MBA	950- 1010
	5. New Business		
A/D	<ul><li>a. DUR Board Activities</li><li>i. Summary of MCO Best Practices</li></ul>	Randall Stafford, MD, PhD	1010- 1050
	Morning Break		1050- 1055
R/D	b. Health Plan Presentation: "The Safe Choice Program: A Response to the Opiate Crisis"	Beth Stewart, MD and Nick Osterman, MA, LMFT [Anthem Blue Cross]	1055- 1140
R/A/D	c. DUR Annual Report to CMS: FFY 2018 MCO Summary	Pauline Chan, RPh, MBA	1140- 1230
Lunch Break			1230- 130
R/D	d. Recap of morning action items	Hannah Orozco, PharmD	130- 135
R/A/D	<ul> <li>e. Retrospective DUR</li> <li>i. Global Annual Report: FFY 2018</li> <li>ii. FFS Quarterly Report: 1Q2019 (Jan – Mar 2019)</li> <li>iii. Biennial Report 2018: Part II</li> </ul>	Amanda Fingado, MPH	135- 210

		2	
R/A/D	iv. Review: Gabapentenoids  f. Review of DUR Publications i. Bulletin (February 2019): MEDD Updates ii. Alert (March 2019): Fluoroquinolones iii. Alert (April 2019): Sudden Discontinuation of Opioids iv. Discussion/Recommendations for Future Bulletins	Shalini Lynch, PharmD	210- 225
R/A/D	<ul> <li>g. Prospective DUR: Fee-for-Service <ul> <li>i. New GCNs for 1Q2019 (Jan – Mar 2019)</li> <li>ii. Update: AT Alert and Gabapentinoids</li> </ul> </li> <li>h. DUR Educational Outreach to Providers: Fee-for-Service <ul> <li>i. Proposal: Zolpidem</li> <li>ii. Proposal: Opioids in Children &lt; 18</li> <li>iii. Outcomes: MEDD – 2019</li> </ul> </li> </ul>	Amanda Fingado, MPH	225- 230
R/I//D	<ul> <li>i. Pharmacy Update</li> <li>i. Policy: AB1114 Implementation</li> <li>ii. DUR goals, priority areas, and related measures</li> <li>iii. Opioids Safety Toolkit for Health Plans</li> <li>iv. CURES 2.0</li> <li>v. Academic Detailing</li> <li>vi. Addressing Complex Drug Regimens</li> <li>vii. SUPPORT Act</li> <li>viii. FFY 2018 DUR Annual Report</li> </ul>	Pauline Chan, RPh, MBA	230- 245
R/D	<ul> <li>j. Recap of afternoon action items</li> <li>k. Looking ahead: Call for future meeting agenda topics</li> <li>i. Presentation by Linette Scott, MD, MPH on Core Set Measures</li> <li>ii. Presentation by Sharon Cummins, PhD and Neal Kohatsu, MD, MPH: "Tobacco Quitlines, Incentives and the Medicaid Population"</li> </ul>	Hannah Orozco, PharmD	245- 250
С	6. Public Comments **		250-
			300
1	7 Consent Arendo		
1	<ul> <li>Consent Agenda</li> <li>a. Meeting feedback</li> <li>b. Next meeting: September 17, 2019 1700 K Street 1st Floor Conference Room Sacramento, CA 95814</li> <li>c. Proposed DUR Board Meeting Dates for 2019/2020: Tuesday, November 19, 2019 Tuesday, March 3, 2020 Tuesday, May 19, 2020 Tuesday, September 15, 2020 Tuesday, November 17, 2020</li> </ul>		
	9 Adjournment		200
Ī	8. Adjournment		300

<sup>\*</sup> REPORT TYPE LEGEND: A: Action; C: Comment; D: Discussion; I: Information; R: Report

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the Global DUR Board.

You can obtain the Global DUR Board agenda from the Medi-Cal DUR Main Menu Web site (http://files.medi-cal.ca.gov/pubsdoco/dur/dur\_home.asp).

<sup>\*\*</sup> Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.